NYSE:PFE - Pfizer Stock Price, Forecast & News

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Monday, December 16th. Investors of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a yield of 4.55%. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer's previous quarterly dividend of $0.36. View Pfizer's Dividend History.

Pfizer announced that its Board of Directors has authorized a share repurchase plan on Friday, December 14th 2018, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) issued its earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.57 by $0.02. The biopharmaceutical company had revenue of $12.69 billion for the quarter, compared to analysts' expectations of $12.73 billion. Pfizer had a return on equity of 27.23% and a net margin of 31.44%. The company's revenue was down 9.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.64 earnings per share. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Pfizer.

Pfizer issued an update on its FY20 earnings guidance on Tuesday, January, 28th. The company provided earnings per share guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

12 Wall Street analysts have issued 12 month target prices for Pfizer's shares. Their forecasts range from $36.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $41.66 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Pfizer.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

News coverage about PFE stock has been trending very negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Pfizer.

Pfizer saw a increase in short interest in February. As of February 14th, there was short interest totalling 61,030,000 shares, an increase of 7.1% from the January 30th total of 56,970,000 shares. Based on an average daily trading volume, of 20,840,000 shares, the short-interest ratio is presently 2.9 days. Approximately 1.1% of the shares of the stock are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Verizon Communications (VZ), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE), AbbVie (ABBV), Bank of America (BAC), Exxon Mobil (XOM) and Walt Disney (DIS).

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (5.27%), Capital World Investors (3.41%), Geode Capital Management LLC (1.61%), Bank of New York Mellon Corp (1.08%), Massachusetts Financial Services Co. MA (0.94%) and Charles Schwab Investment Management Inc. (0.72%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Massachusetts Financial Services Co. MA, PGGM Investments, California Public Employees Retirement System, LSV Asset Management, CI Investments Inc., PNC Financial Services Group Inc. and KBC Group NV. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

PFE stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Renaissance Technologies LLC, Marshall Wace North America L.P., Macquarie Group Ltd., Sanders Capital LLC, Bank of New York Mellon Corp, FIL Ltd and Sound Shore Management Inc. CT. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $33.42.

Pfizer has a market capitalization of $184.95 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

The official website for Pfizer is http://www.pfizer.com/.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.